For those who have been too distracted by swine flu to notice: shares of the biotech company Sequenom have plummeted by 77% after the company announced that the extremely promising initial results for its SEQureDx Down syndrome test – which is designed to detect Down syndrome fetuses using blood samples from pregnant women – were “questionable” and had been mishandled by employees.
GenomeWeb Daily News reports:
As of early February, Sequenom had released data on
its SEQureDx test from a total of 858 samples. It said that the
positive predictive value was 96.6 percent, and the negative predictive
value was 100 percent. But, the firm can no longer rely on that data.
“We are confident in the assay performance,” [Sequenom CEO Harry] Stylli said during the
call. “It’s fair to say that the high-level clinical performance that
we’ve disclosed to you is questionable.”
Stylli said he was limited in what he could say in response to
questions about the incident, due to confidentiality agreements and the
investigation. “The data in question relates to data that goes back to
June — the September and January releases of information — I believe
that information is now suspect … I can’t really go into any of the
details because of the confidentiality considerations and because the
investigation is not complete,” he said.
Here’s Sequenom’s share price over the last five days: